When was Passkey Therapeutics founded?

Passkey Therapeutics was founded in 2022.

Where is Passkey Therapeutics located?

Passkey Therapeutics is headquartered in Cambridge, United States.

Who is the current CEO of Passkey Therapeutics?

Bruce Beutel of Passkey Therapeutics. They have also founded 1 company.

How many employees does Passkey Therapeutics have?

As of Jun 30, 2026, the latest employee count at Passkey Therapeutics is 9.

Is Passkey Therapeutics a funded company?

Passkey Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Passkey Therapeutics rank among its competitors?

Passkey Therapeutics ranks 92nd amongst 364 active competitors, of which 92 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Passkey Therapeutics?

Passkey Therapeutics' top competitors include BridgeBio, Alnylam and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Passkey Therapeutics - 2026 Company Profile, Team & Competitors

Passkey Therapeutics is an unfunded company based in Cambridge (United States), founded in 2022 by Soumya Ray, William Chen and Bruce Beutel. It operates as a Developer of multifunctional therapeutics targeting rare combinations of proteins. Passkey Therapeutics has not raised any funding yet. The company has 364 active competitors, including 92 funded and 104 that have exited. Its top competitors include companies like BridgeBio, Alnylam and Alexion.

Company Details

Developer of multifunctional therapeutics targeting rare combinations of proteins. The company uses a proprietary platform Locksmith platform to identify and address complex biological underlying conditions by targeting rare combinations of proteins.

Website: passkeytx.com
Email ID: *****@passkeytx.com

Key Metrics

Founded Year

2022

Location

Cambridge, United States

Stage

Unfunded

Ranked

92^nd among 364 active competitors

Employee Count

9 as on Jun 30, 2026

Similar Companies

BridgeBio & 402 more

View Passkey Therapeutics' full profile

Passkey Therapeutics has not raised any funding rounds yet.

The founders of Passkey Therapeutics are Soumya Ray, William Chen and Bruce Beutel. Bruce Beutel is the CEO of Passkey Therapeutics.

Here are the details of Passkey Therapeutics' key team members:

Soumya Ray: Co-Founder of Passkey Therapeutics.
William Chen: Co-Founder & CTO of Passkey Therapeutics.
Contact Info: 1 email address
Bruce Beutel: Co-Founder & CEO of Passkey Therapeutics.

View details of Passkey Therapeutics's Founder profiles and Board Members

Passkey Therapeutics' employee count trend

Passkey Therapeutics has 9 employees as of Jun 26. Here is Passkey Therapeutics's employee count trend over the years:

Employee count trend for Passkey Therapeutics

Uncover Passkey Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Passkey Therapeutics include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Passkey Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
9th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	69/100
92nd	Passkey Therapeutics 2022, Cambridge (United States), Unfunded	Developer of multifunctional therapeutics targeting rare combinations of proteins	-	-	48/100